Practical application of the continual reassessment method to a phase I dose-finding trial in advanced breast cancer

Drug Information Journal

Volumn 41, Issue 6, 2007, Pages 691-700

  Morita, Satoshi ^a,i   Toi, Masakazu ^b   Saji, Shigehira ^b   Iwata, Hiroji ^c   Ohno, Shinji ^d   Ito, Yoshinori ^e   Kobayashi, Tadashi ^f   Hozumi, Yasuo ^g   Sakamoto, Junichi ^h  

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g JICHI MEDICAL UNIVERSITY   (Japan)

^h NAGOYA UNIVERSITY   (Japan)

ⁱ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Combination therapy; Continual reassessment method; Dose finding; Phase I trial

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; EPIRUBICIN;

ALOPECIA; ARTICLE; BAYES THEOREM; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DOSE CALCULATION; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG FEVER; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; STATISTICAL MODEL; THROMBOCYTOPENIA; TOXICITY; VOMITING;

EID: 36248956697     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150704100601     Document Type: Article

References (25)

1. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990;46:33-48.
2. Ishizuka N, Morita S. Practical implementation of the continual reassessment method. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology. 2nd ed. New York, NY: CRC Press; 2005.
3. Ishizuka N, Ohashi Y. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Stat Med. 2001;20:2661-2681.
4. Thall PF, Lee SJ. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity. Int J Gynecol Cancer. 2003;13:251-261.
5. O'Quigley J. Phase I and phase I/II dose finding algorithms using continual reassessment method. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology. 2nd ed. New York, NY: CRC Press; 2005.
6. Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clin Trials. 2006;3:57-71.
7. Bonnefoi H, Biganzoli L, Mauriac L, et al. An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (CEX) as primary treatment for large operable or locally advanced/inflammatory breast cancer. Eur J Cancer. 2003;39:277-283.
8. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485-493.
9. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759-1768.
10. Bonnefoi H, Biganzoli L, Cufer T, et al. An EORTC phase 1 study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer. Breast Cancer Res Treat. 2001;70:55-63.
11. Iwata H, Nakamura S, Toi M, et al. Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma. Breast Cancer. 2005;12:99-103.
12. Eisen T, Smith IE, Johnston S, et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol. 1998;16:1350-1357.
13. Morita S, Toi M, Kobayashi T, et al. Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer. Jpn J Clin Oncol. 2004;34:104-106.
14. Chevret S. The continual reassessment method in cancer phase I clinical trials: a simulation study. Stat Med. 1993;12:1093-1108.
15. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase 1 studies. Stat Med. 1995;14:1149-1161.
16. Mick R, Ratain MJ. Model-guided determination of maximum tolerated dose in phase 1 clinical trials: evidence for increased precision. J Natl Cancer Inst. 1993;85:217-223.
17. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase 1 clinical trials in oncology. J Natl Cancer Inst. 1997;89:1138-1147
18. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM. A comparison of two phase 1 trial designs. Stat Med. 1994;13:1799-1806.
19. Babb J, Rogatko A, Zacks S. Cancer phase 1 clinical trials: efficient dose escalation with overdose control. Stat Med. 1998;17:1103-1120.
20. Potter DM. Adaptive dose finding for phase 1 clinical trials of drugs used for chemotherapy of cancer. Stat Med. 2002;21:1805-1823.
21. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 2004;60:684-693.
22. Shen LZ, O'Quigley J. Consistency of continual reassessment method under model misspecification. Biometrika. 1996;83:395-405.
23. O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics. 1996;52:673-684.
24. Kang S, Ahn C. The expected toxicity rate at the maximum tolerated dose in the standard phase 1 cancer clinical trial design. Drug Inf J. 2001;35:1189-1199.
25. Garthwaite PH, Kadane JB, O'Hagan A. Statistical methods for eliciting probability distributions. J Am Stat Assoc. 2005;100:680-701.